sofosbuvir has been researched along with Acute Liver Injury, Drug-Induced in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
Authors | Studies |
---|---|
Nabavi, N; Pourahmad, J; Yousefsani, BS | 1 |
Wahid, B | 1 |
Aldersley, MA; Dyson, JK; Foster, GR; Harrison, L; Hutchinson, J; McPherson, S; Rotimi, O; Tiniakos, D | 1 |
Tseng, A; Wong, DK | 1 |
Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P | 1 |
5 other study(ies) available for sofosbuvir and Acute Liver Injury, Drug-Induced
Article | Year |
---|---|
Contrasting Role of Dose Increase in Modulating Sofosbuvir-Induced Hepatocyte Toxicity.
Topics: Animals; Antiviral Agents; Cells, Cultured; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Hepatitis C; Hepatocytes; Humans; Male; Oxidative Stress; Primary Cell Culture; Rats; Sofosbuvir | 2020 |
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis.
Topics: Aged; Antitubercular Agents; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Coinfection; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Male; Pyrrolidines; Ribavirin; Sofosbuvir; Tuberculosis; Valine | 2019 |
Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use.
Topics: Adult; Aged; Antiviral Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Male; Ribavirin; Sofosbuvir; Viral Nonstructural Proteins | 2016 |
Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients.
Topics: Antiviral Agents; Benzimidazoles; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepatitis C; HIV Infections; Humans; Sofosbuvir | 2016 |
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load | 2017 |